Login
$VRDN
$30.76 -$0.11 (0.36%) Live

$VRDN SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 SCHEDULE 13G
09 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

- $24.7 million in Lumvoa™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -

20 Aug 2026 SCHEDULE 13G
20 Aug 2026 Form 4: Tousignant Jennifer, Chief Legal Officer

Sold 14,212 shares ($348K) · Received 10,000 shares by exercise or conversion ($144K)

19 Aug 2026 144
18 Aug 2026 Form 4: Tripuraneni Radhika, Chief Medical Officer

Received 40,000 shares by exercise or conversion ($528K)

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 SCHEDULE 13G
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

- Lumvoa™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of

02 Jul 2026 Form 4: Cain Christopher W., Director

Granted 32,341 Stock Option (Right to Buy)

02 Jul 2026 Form 4: Ajer Jeffrey Robert, Director

Granted 32,341 Stock Option (Right to Buy)

02 Jul 2026 Form 4: Moses Jennifer K., Director

Granted 32,341 Stock Option (Right to Buy)

02 Jul 2026 Form 4: Gheuens Sarah, Director

Granted 32,341 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support